QuidelOrtho Corporation (NASDAQ:QDEL) Given Average Recommendation of “Reduce” by Brokerages

QuidelOrtho Corporation (NASDAQ:QDEL) has received a consensus rating of “Reduce” from the six brokerages that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $13.6250.

QDEL has been the subject of a number of research reports. Jefferies Financial Group reissued a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Friday, July 17th. Zacks Research downgraded QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 12th. Finally, UBS Group reissued a “neutral” rating and issued a $12.00 target price on shares of QuidelOrtho in a research report on Thursday, May 7th.

QuidelOrtho Stock Up 2.7%

Shares of NASDAQ:QDEL opened at $15.32 on Friday. The company has a market capitalization of $1.05 billion, a PE ratio of -0.99 and a beta of 0.68. The company has a current ratio of 1.39, a quick ratio of 0.76 and a debt-to-equity ratio of 1.43. QuidelOrtho has a twelve month low of $9.92 and a twelve month high of $35.58. The firm has a 50 day simple moving average of $15.91 and a 200-day simple moving average of $16.05.

QuidelOrtho (NASDAQ:QDEL) last issued its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.18. The business had revenue of $630.90 million during the quarter, compared to analysts’ expectations of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, equities analysts predict that QuidelOrtho will post 0.75 EPS for the current fiscal year.

Institutional Investors Weigh In On QuidelOrtho

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its position in shares of QuidelOrtho by 1,218.7% during the first quarter. Royal Bank of Canada now owns 80,193 shares of the company’s stock worth $2,803,000 after acquiring an additional 74,112 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in QuidelOrtho by 10.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company’s stock valued at $7,987,000 after purchasing an additional 21,968 shares during the last quarter. Focus Partners Wealth raised its position in QuidelOrtho by 210.9% in the 1st quarter. Focus Partners Wealth now owns 20,454 shares of the company’s stock valued at $715,000 after purchasing an additional 13,876 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in QuidelOrtho during the 2nd quarter worth $1,313,000. Finally, EverSource Wealth Advisors LLC boosted its stake in QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock worth $93,000 after purchasing an additional 2,309 shares during the period. Hedge funds and other institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.